Tenax Therapeutics Confirms Nasdaq Listing for Common Stock
Ticker: TENX · Form: 8-K · Filed: Jan 19, 2024 · CIK: 34956
| Field | Detail |
|---|---|
| Company | Tenax Therapeutics, INC. (TENX) |
| Form Type | 8-K |
| Filed Date | Jan 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, listing-status, administrative
TL;DR
**TENX confirms Nasdaq listing, no new news.**
AI Summary
Tenax Therapeutics, Inc. filed an 8-K on January 18, 2024, to update its registration information, specifically confirming its Common Stock, $0.0001 par value per share, is registered on The Nasdaq Stock Market LLC under the trading symbol TENX. This filing is a routine update, indicating no major operational or financial changes. For investors, this simply reaffirms the company's listing status, which is important for liquidity and trading, but doesn't signal new opportunities or risks.
Why It Matters
This filing confirms Tenax Therapeutics' continued listing on Nasdaq, which is crucial for investor confidence and the liquidity of its shares. It ensures the stock remains easily tradable for current and prospective shareholders.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no material financial or operational changes, posing minimal risk.
Analyst Insight
Investors should view this as a routine administrative update that doesn't warrant any immediate action. It simply confirms existing listing information, so no new investment decisions are indicated by this filing alone.
Key Numbers
- $0.0001 — par value per share (the stated par value of Tenax Therapeutics' Common Stock)
Key Players & Entities
- Tenax Therapeutics, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market LLC (company) — the exchange where Tenax's stock is registered
- TENX (company) — the trading symbol for Tenax Therapeutics
- $0.0001 (dollar_amount) — par value per share of Common Stock
- January 18, 2024 (date) — date of earliest event reported in the 8-K
FAQ
What is the specific event reported in this 8-K filing by Tenax Therapeutics, Inc.?
The 8-K reports on 'Other Events' and specifically confirms that Tenax Therapeutics, Inc.'s Common Stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Act and listed on The Nasdaq Stock Market LLC under the trading symbol TENX, as of January 18, 2024.
What is the trading symbol for Tenax Therapeutics, Inc. on The Nasdaq Stock Market LLC?
According to the filing, the trading symbol for Tenax Therapeutics, Inc.'s Common Stock on The Nasdaq Stock Market LLC is TENX.
What is the par value per share of Tenax Therapeutics, Inc.'s Common Stock?
The filing states that the par value per share of Tenax Therapeutics, Inc.'s Common Stock is $0.0001.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 18, 2024.
What is the address of Tenax Therapeutics, Inc.'s principal executive offices?
The principal executive offices of Tenax Therapeutics, Inc. are located at 101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina 27517.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-01-19 16:30:25
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share TENX The Nasdaq
- $1.00 — y's common stock had a closing price of $1.00 or greater for the ten consecutive trad
Filing Documents
- tenx_8k.htm (8-K) — 21KB
- 0001654954-24-000770.txt ( ) — 141KB
- tenx-20240118.xsd (EX-101.SCH) — 6KB
- tenx-20240118_lab.xml (EX-101.LAB) — 14KB
- tenx-20240118_cal.xml (EX-101.CAL) — 1KB
- tenx-20240118_pre.xml (EX-101.PRE) — 9KB
- tenx-20240118_def.xml (EX-101.DEF) — 2KB
- tenx_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On January 18, 2024, Tenax Therapeutics, Inc. (the "Company") received written notification from the Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company's common stock had a closing price of $1.00 or greater for the ten consecutive trading days from January 3, 2024 to January 17, 2024 and that as a result the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") and that the matter is now closed. As previously reported, on March 29, 2023, Nasdaq notified the Company that for the last 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to the Bid Price Rule. On September 28, 2023, the Company received formal notice that Nasdaq had granted the Company's request for an extension through March 25, 2024 to evidence compliance with the Bid Price Rule. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 19, 2024 Tenax Therapeutics, Inc. By: /s/ Christopher T. Giordano Christopher T. Giordano President and Chief Executive Officer 3